Natus acquired all outstanding shares of Sonamed capital stock for $9 million cash, exclusive of direct costs of the acquisition.
Jim Hawkins, president and CEO of Natus, said: We are very pleased to announce the completion of this acquisition. We expect the Clarity screener to further fill out our product line in newborn hearing screening. With two-thirds of Sonamed’s revenue coming from disposable supplies, combined with their high gross profit margin, we believe Sonamed’s products will be an ideal fit for our business model.